SCHEMBL437883

SCHEMBL437883

CCC(=O)N(C(=O)CC(=O)NN(C)C(=S)C1CC1)N(C)C(=S)C1CC1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL440512 0.89 HSP90AA1 (0.31) HSP90AA1HSP90AB1
SCHEMBL10049993 0.81 HSP90AA1 (0.43) HSP90AA1HSP90AB1
SCHEMBL14292615 0.75 HSP90AA1 (0.36) HSP90AA1HSP90AB1
SCHEMBL13654193 0.75 HSP90AA1 (0.39) HSP90AA1HSP90AB1
SCHEMBL13238124 0.75 HSP90AA1 (0.41) HSP90AA1HSP90AB1
SCHEMBL13238109 0.75 HSP90AA1 (0.41) HSP90AA1HSP90AB1
SCHEMBL13238115 0.73 CES2 (0.40) HSP90AA1HSP90AB1
SCHEMBL439019 0.72 HSP90AA1 (0.30) HSP90AA1HSP90AB1
SCHEMBL13843473 0.72 HSP90AA1 (0.36) HSP90AA1HSP90AB1
SCHEMBL13292803 0.71 HSP90AA1 (0.32) HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308872-B2 Composite marking based on chiral liquid crystal precursors and modifying resins SICPA HOLDING SA (CH) 2019-06-04 US disclosed
EP-2714412-B1 SUBSTRATE WITH A MODIFIED LIQUID CRYSTAL POLYMER MARKING SICPA HOLDING SA (CH) 2019-03-13 EP disclosed
EP-3126149-B1 MARKING COMPRISING A CHIRAL LIQUID CRYSTAL POLYMER AND A LUMINESCENT SUBSTANCE SICPA HOLDING SA (CH) 2018-12-26 EP disclosed
EP-3019576-B1 MARKING COMPRISING A PRINTABLE CODE AND A CHIRAL LIQUID CRYSTAL POLYMER LAYER SICPA HOLDING SA (CH) 2018-11-07 EP disclosed
US-9987866-B2 Marking comprising a chiral liquid crystal polymer and a luminescent substance SICPA HOLDING SA (CH) 2018-06-05 US disclosed
US-9834031-B2 Chiral liquid crystal polymer layer or pattern comprising randomly distributed craters therein SICPA HOLDING SA (CH) 2017-12-05 US disclosed
US-9816031-B2 Composite marking based on chiral liquid crystal precursors SICPA HOLDING SA (CH) 2017-11-14 US disclosed
EP-2414986-B1 IDENTIFICATION AND AUTHENTICATION USING POLYMERIC LIQUID CRYSTAL MATERIAL MARKINGS SICPA HOLDING SA (CH) 2017-06-14 EP disclosed
US-20170120649-A1 MARKING COMPRISING A CHIRAL LIQUID CRYSTAL POLYMER AND A LUMINESCENT SUBSTANCE SICPA HOLDING SA (CH) 2017-05-04 US disclosed
EP-2649155-B1 SIMPLIFIED CONTROL OF COLOR SHIFTING PROPERTIES OF A CHIRAL LIQUID CRYSTAL POLYMER SICPA HOLDING SA (CH) 2017-03-15 EP disclosed
WO-2012163778-A1 SUBSTRATE WITH A MODIFIED LIQUID CRYSTAL POLYMER MARKING SICPA HOLDING SA (CH) 2012-12-06 WO disclosed
US-20120141697-A1 COMPOSITE MARKING BASED ON CHIRAL LIQUID CRYSTAL PRECURSORS SICPA HOLDING SA (CH) 2012-06-07 US disclosed
US-20120141745-A1 SIMPLIFIED CONTROL OF COLOR SHIFTING PROPERTIES OF A CHIRAL LIQUID CRYSTAL POLYMER SICPA HOLDING SA (CH) 2012-06-07 US disclosed
US-20120061470-A1 IDENTIFICATION AND AUTHENTICATION USING POLYMERIC LIQUID CRYSTAL MATERIAL MARKINGS SICPA HOLDING SA (CH) 2012-03-15 US disclosed
US-20120065235-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-03-15 US disclosed
US-20120065235-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-03-15 US disclosed
US-20120065235-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-03-15 US disclosed
US-20110135890-A1 CHIRAL LIQUID CRYSTAL POLYMER MARKING SICPA HOLDING S.A. (CH) 2011-06-09 US disclosed
US-20110135889-A1 MARKING BASED ON CHIRAL LIQUID CRYSTAL POLYMERS SICPA HOLDING S.A. (CH) 2011-06-09 US disclosed
US-20110135853-A1 MODIFIED MARKING BASED ON CHIRAL LIQUID CRYSTAL POLYMERS SICPA HOLDING S.A. (CH) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120061470-A1 IDENTIFICATION AND AUTHENTICATION USING POLYMERIC LIQUID CRYSTAL MATERIAL MARKINGS INCENP, MKI67, ATG4B HSP90AA1 1665/4885HSP90AB1 3174/4885
US-20120141745-A1 SIMPLIFIED CONTROL OF COLOR SHIFTING PROPERTIES OF A CHIRAL LIQUID CRYSTAL POLYMER CRY1, SET, RCC1 HSP90AA1 4530/4885HSP90AB1 4741/4885
US-20120065235-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS HSP90AB1, HSF1, HSP90B1 HSP90AA1 6/4885HSP90AB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.